All In Biotech

Drug Trial Radar · NCT07898501

SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis

Cellular Composition and Secretome Characteristics of Autologous Adipose-Derived Stromal Vascular Fraction and Biological and Clinical Responses Following Intra-Articular Injection in Patients With Knee Osteoarthritis: A Prospective Observational Study

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Sep 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Yonsei UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, single-center observational study will enroll 20 adults aged 40 to 75 years with Kellgren-Lawrence grade II or III knee osteoarthritis who have already been scheduled for an intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF) as clinical care. The study does not assign treatment, use a control group, or randomize participants. After preparation of the therapeutic SVF, residual adipose tissue will be processed independently with a new disposable kit to obtain research-only SVF. No additional adipose tissue will be harvested for research, and research-only SVF will not be injected. Cellular composition and secretome characteristics of research-only SVF will be measured. Synovial fluid biomarkers will be assessed before injection and at 6 months using the same 12-analyte panel. Patient-reported outcomes and knee radiographs will also be compared between baseline and 6 months. CGBio provides research funding and research-only processing kits without involvement in study conduct, analysis, or publication decisions.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Autologous adipose-derived stromal vascular fraction intra-articular injectionBiological

    As clinical care, approximately 200 mL of abdominal lipoaspirate is collected under general anesthesia after tumescent infiltration. SVF is prepared using the CGBio Cell Unit closed automated processing system, concentrated to approximately 5 mL, and injected once into the affected knee. The decision to perform this treatment precedes research enrollment. Research-only SVF is separately prepared from residual adipose tissue using a new kit and is never administered to participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Red blood cell contamination of research-only SVFTime frame: Baseline (procedure day)
  2. Total nucleated cell count of research-only SVFTime frame: Baseline (procedure day)
  3. MSC-like stromal progenitor cell compositionTime frame: Baseline (procedure day)
  4. CD34-positive adipose stromal progenitor cell compositionTime frame: Baseline (procedure day)
  5. Research-only SVF secretome analyte concentrationsTime frame: Baseline (procedure day)
  6. Change from baseline in synovial fluid biomarker concentrations at 6 monthsTime frame: Immediately before injection and 6 months after injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yonsei University College of Medicine

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.